| Accession |
PRJCA024102 |
| Title |
A prospective, pilot study of first line osimertinib with or without savolitinib in de novo MET positive, EGFR-mutant NSCLCs (FLOWERS) |
| Relevance |
Medical |
| Data types |
Genome sequencing
|
| Organisms |
Homo sapiens
|
| Description |
To explore the objective response of osimertinib plus savolitinib or osimertinib monotherapy as first-line therapy in de novo MET positive, EGFRm NSCLC |
| Sample scope |
Multiisolate |
| Release date |
2024-03-06 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Astrazeneca Investment (China) Co., Ltd
|
|
CTONG2008-ESR20-20862
|
|
|
|
| Submitter |
Jiayi
Xiao (kary@chinactong.com)
|
| Organization |
Guangdong Association of Clinical Trials |
| Submission date |
2024-03-06 |
